IVUMO-SP – Aceclofenac 100mg + Paracetamol 325mg + Serratiopeptidase 15mg Tablets
The label claim on this combination is standard across the market. What is not standard is whether the Serratiopeptidase survives to act. Serratiopeptidase is a proteolytic enzyme denatured by gastric acid, so the entire enzyme component depends on enteric coating integrity — if the coating fails in the stomach, the tablet delivers an Aceclofenac and Paracetamol combination and nothing more. IVUMO-SP is manufactured with enteric-coated Serratiopeptidase for release in the intestine.
Product Specifications
Brand Name: IVUMO-SP
Composition: Aceclofenac 100mg + Paracetamol 325mg + Serratiopeptidase 15mg
Dosage Form: Tablet, with enteric-coated Serratiopeptidase
Therapeutic Category: Orthopaedics, Pain and Inflammation Management
Manufacturing: GMP certified facility
Prescription Status: Schedule H
Storage: Store below 25°C, protect from light and moisture
Composition
Aceclofenac — 100 mg — NSAID; inhibits cyclo-oxygenase to reduce prostaglandin-mediated pain and inflammation
Paracetamol — 325 mg — Centrally acting analgesic and antipyretic
Serratiopeptidase — 15 mg (enteric coated) — Proteolytic enzyme; assists resolution of inflammatory exudate and tissue oedema
Mechanism of Action
The three components act on different stages of the same inflammatory process rather than reinforcing a single pathway. Aceclofenac inhibits cyclo-oxygenase, reducing prostaglandin synthesis at the site of injury and addressing both pain and the inflammatory response driving it. Paracetamol acts centrally, contributing analgesia and antipyresis through a mechanism distinct from peripheral prostaglandin inhibition, which allows meaningful pain control at a lower NSAID dose than would otherwise be required.
Serratiopeptidase works on the physical consequence of inflammation rather than its signalling. As a proteolytic enzyme it assists breakdown of fibrin and inflammatory exudate, supporting drainage of oedema from the affected tissue. Reducing that fluid accumulation relieves mechanical pressure on nociceptors and improves local perfusion, which is why the enzyme is included in post-traumatic and post-surgical presentations where swelling itself is a substantial part of the complaint.
Why Enteric Coating Determines Outcome
Serratiopeptidase is a protein. Exposure to gastric acid denatures it, which is why the enzyme must be enteric coated to reach the small intestine intact for absorption. A tablet whose coating dissolves prematurely delivers a degraded enzyme, and the clinical difference from a plain Aceclofenac and Paracetamol combination narrows accordingly.
This is the point of genuine variability in a composition where label claims are otherwise identical across the market, and it is where formulation and manufacturing standards translate directly into clinical performance.
Clinical Applications
- Post-traumatic pain and swelling
- Post-surgical and post-operative inflammation and oedema
- Acute musculoskeletal pain with an inflammatory component
- Soft tissue injuries, sprains and strains
- Osteoarthritis and rheumatoid arthritis, as prescribed
- Dental pain and post-extraction inflammation
- Low back pain with associated inflammation
Prescriber Profile
Orthopaedic surgeons form the primary prescribing base, particularly in post-traumatic and post-surgical management where swelling accompanies pain. Dental surgeons prescribe it in post-extraction and post-procedural inflammation. General surgeons account for post-operative use, and general physicians and physiotherapy-referring practitioners for acute musculoskeletal presentations.
Dosage and Administration
As prescribed by a Registered Medical Practitioner. Tablets are swallowed whole and must not be crushed or chewed, as this destroys the enteric coating protecting the Serratiopeptidase. Best taken after food. This is a Schedule H drug — sale by retail is permitted only against the prescription of a Registered Medical Practitioner.
Safety Information
As an NSAID-containing combination, gastric and renal considerations apply. Use with caution or avoid in patients with active peptic ulcer disease, a history of gastrointestinal bleeding, significant renal impairment, or uncontrolled hypertension and cardiac disease. Concurrent use of other NSAIDs should be avoided.
The Paracetamol component means total daily Paracetamol intake from all sources must be accounted for, as exceeding recommended limits carries a risk of hepatic injury — relevant where patients may be taking separate Paracetamol-containing preparations. Not indicated in significant hepatic impairment. Serratiopeptidase requires caution in patients on anticoagulant therapy or with bleeding disorders. Store below 25°C, protect from light and moisture. Keep out of reach of children.
Range Positioning
This composition is among the most widely prescribed in Indian orthopaedic practice, which makes it a stocking necessity rather than an optional addition — but also means it is largely traded on rate. IVUMO-SP is positioned on formulation integrity instead: the enteric coating on the Serratiopeptidase is what separates a functioning three-component tablet from a two-component one, and that is a defensible conversation with a prescriber who has seen inconsistent results from cheaper alternatives.
PCD Pharma Franchise Availability
IVUMO-SP is available across India for PCD Pharma Franchise association, with territory rights allotted on a monopoly basis subject to availability. Associates receive promotional inputs and product literature across the orthopaedics and pain management range. Trade enquiries may be directed to Eridanus Healthcare.
Frequently Asked Questions
Why does Serratiopeptidase need to be enteric coated?
Serratiopeptidase is a protein and is denatured by gastric acid. Enteric coating protects it through the stomach so it reaches the small intestine intact for absorption. Without effective coating, the enzyme component is substantially degraded before it can act.
What does Serratiopeptidase add over Aceclofenac and Paracetamol alone?
Aceclofenac and Paracetamol address pain signalling. Serratiopeptidase acts on the physical inflammatory exudate, assisting drainage of oedema and reducing mechanical pressure on tissue — relevant where swelling is itself a significant part of the presentation.
Can the tablet be crushed or split?
No. Crushing or chewing destroys the enteric coating protecting the Serratiopeptidase, removing the benefit of the enzyme component.
What are the main safety considerations?
NSAID-related gastric and renal precautions apply, total daily Paracetamol intake from all sources must be accounted for, and caution is required in patients on anticoagulants or with bleeding disorders.
Why should a distributor stock this composition?
Aceclofenac, Paracetamol and Serratiopeptidase is among the highest-volume orthopaedic prescriptions in India, generating consistent year-round demand across orthopaedic, dental and surgical practice rather than seasonal movement.
How does IVUMO-SP compete in a segment traded largely on price?
Through formulation integrity. Since the enzyme component depends entirely on enteric coating quality, two tablets with identical label claims can differ in clinical effect — which gives a field team a technical argument rather than a rate negotiation.
Which prescribers form the primary target base?
Orthopaedic surgeons and dental surgeons are the primary prescribers, with general surgeons and general physicians as secondary coverage — relevant when building an orthopaedics and pain portfolio through PCD Pharma Franchise association.
How may a distributor enquire about territory rights?
Distributors and pharmaceutical professionals holding a valid Drug Licence and GST registration may contact Eridanus Healthcare to discuss availability and terms.